Evidence map›Paper›PMID 31437274›Full record

ReviewNeuro-oncology2020

Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Norbert Galldiks, Martin Kocher, Garry Ceccon, Jan-Michael Werner, Anna Brunn, Martina Deckert, Whitney B Pope, Riccardo Soffietti, Emilie Le Rhun, Michael Weller and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022
    Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Are Dual-PhaseCancers · 2024
    Article
  19. Review
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Norbert GalldiksDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Martin KocherInstitute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
Garry CecconDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jan-Michael WernerDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Anna BrunnInstitute of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Martina DeckertInstitute of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Whitney B PopeDepartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Riccardo SoffiettiDepartment of Neuro-Oncology, University and City of Health and Science Hospital, Turin, Italy.
Emilie Le RhunNeuro-Oncology, General and Stereotaxic Neurosurgery Service, University Hospital Lille, Lille, France.
Michael WellerDepartment of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Jörg C TonnDepartment of Neurosurgery, Ludwig Maximilians University of Munich, Munich, Germany.
Gereon R FinkDepartment of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Karl-Josef LangenInstitute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted therapy (TT) has dramatically improved the prognosis of various cancer types. However, following ICI therapy or TT-either alone (especially ICI) or in combination with radiotherapy-imaging findings on anatomical contrast-enhanced MRI can be unpredictable and highly variable, and are often difficult to interpret regarding treatment response and outcome. This review aims at summarizing the imaging challenges related to TT and ICI monotherapy as well as combined with radiotherapy in patients with brain metastases, and to give an overview on advanced imaging techniques which potentially overcome some of these imaging challenges. Currently, major evidence suggests that imaging parameters especially derived from amino acid PET, perfusion-/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional information for the differentiation of treatment-induced changes from brain metastases recurrence and the evaluation of treatment response.

Indexed as

Brain NeoplasmsDisease ProgressionHumansImmune Checkpoint InhibitorsImmunotherapyMolecular Targeted TherapyNeuroimagingTreatment OutcomeImmune Checkpoint Inhibitorsbrain metastasisFET PETimmune checkpoint inhibitorslung cancermelanomaradiomics

Identifiers

PMID31437274
PMCPMC6954406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.